About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Follow-up of Migraine Patients on Eptinezumab

Follow-up of Migraine Patients on Eptinezumab

NCT06446804·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Centre Hospitalier Universitaire de Nīmes

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adult patients suffering from severe migraine with at least 8 migraine days per month
* Patients who have failed at least 2 disease-modifying treatments,
* Patients treated with quarterly infusions of eptinezumab since March 2023 in a day hospital at Saint-Denis Hospital and Nîmes University Hospital.

You may not be if

Patient refusing to participate

The record

StatusCompleted

PhaseNo phase

Taking part60

StartedJun 2024

UpdatedNov 1, 2024

Conditions

Where2

CHU de Nîmes
Nîmes, France
CH de Saint Denis
Saint-Denis, France